Premium
Role of angiotensin AT 1 and AT 2 receptors in cardiac hypertrophy and cardiac remodelling
Author(s) -
Zhu YiChun,
Zhu YiZhun,
Lu Ning,
Wang MingJie,
Wang YanXia,
Yao Tai
Publication year - 2003
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2003.03942.x
Subject(s) - receptor , angiotensin ii , angiotensin receptor , medicine , endocrinology , angiotensin ii receptor type 1 , muscle hypertrophy , renin–angiotensin system , biology , blood pressure
Summary 1. Left ventricular hypertrophy (LVH) is an independent cardiovascular risk factor. Angiotensin AT 1 receptor antagonism has been considered as a specific approach to block the renin–angiotensin system and been demonstrated to be able to prevent or regress LVH by interfering with the remodelling process of the heart. 2. Angiotensin AT 1 receptor blockade induces a marked increase in angiotensin (Ang) II, which may stimulate the AT 2 receptors. Gene expression of AT 1 and AT 2 receptors increases in a time‐dependent manner in cardiac remodelling following myocardial infarction. 3. Considerable efforts have been made to clarify the role of AT 2 receptors in cardiac hypertrophy and remodelling since the mid‐1990s, resulting in controversial reports: the AT 2 receptor mediates actions either opposite to or in coordination with those of the AT 1 receptor. Moreover, there are many reports of no significant effects mediated by AT 2 receptors. 4. Based on the studies reviewed in the present article, we assume that the predominant effect of AngII in cardiac hypertrophy and cardiac remodelling is growth promoting and that this effect is mediated mainly via AT 1 receptors. The AT 2 receptors may affect the hypertrophic process by interacting with other cardiac membrane proteins, enzymes and autacoids. Before coming to a conclusion as to whether AT 2 receptor stimulation or antagonism is beneficial to the heart, more studies should be performed in different LVH models, especially long‐term treatment protocols in vivo .